BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 19195035)

  • 1. Update on the therapy for myelodysplastic syndrome.
    Kasner MT; Luger SM
    Am J Hematol; 2009 Mar; 84(3):177-86. PubMed ID: 19195035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on the treatment of myelodysplastic syndromes.
    Kurtin SE; Demakos EP
    Clin J Oncol Nurs; 2010 Jun; 14(3):E29-44. PubMed ID: 20529786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes.
    Fenaux P; Ades L
    Leuk Res; 2009 Dec; 33 Suppl 2():S7-11. PubMed ID: 20004796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing patients with low-risk MDS.
    Sekeres M; Cosgrove D; Falco A
    Clin Adv Hematol Oncol; 2006 Jul; 4(7 Suppl 16):1-10; quiz 11-2. PubMed ID: 17139240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel agents for the management of myelodysplastic syndromes.
    Meletis J; Viniou N; Terpos E
    Med Sci Monit; 2006 Sep; 12(9):RA194-206. PubMed ID: 16940944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment strategies and issues in low/intermediate-1-risk myelodysplastic syndrome (MDS) patients.
    Bowen DT
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S16-23. PubMed ID: 16085013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow transplant in myelodysplastic syndromes: new technologies, same questions.
    Giralt S
    Curr Hematol Rep; 2005 May; 4(3):200-7. PubMed ID: 15865872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in myelodysplastic syndrome: nursing implications of azacitidine.
    Demakos EP; Linebaugh JA
    Clin J Oncol Nurs; 2005 Aug; 9(4):417-23. PubMed ID: 16117208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematopoietic growth factors in myelodysplastic syndromes.
    Blinder VS; Roboz GJ
    Curr Hematol Rep; 2003 Nov; 2(6):453-8. PubMed ID: 14561388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleoside analogs and antimetabolite therapies for myelodysplastic syndrome.
    Foss FM
    Best Pract Res Clin Haematol; 2004 Dec; 17(4):573-84. PubMed ID: 15494295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New agents in myelodysplastic syndromes.
    Jabbour EJ; Giles FJ
    Curr Hematol Rep; 2005 May; 4(3):191-9. PubMed ID: 15865871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-azacitidine: An alternative treatment of myelodysplastic syndromes in patient with refractory response to hematopoietic growth factor, a case report and review of literatures.
    Suwanawiboon B; Sumida KN
    Hawaii Med J; 2004 Jan; 63(1):14-6, 25. PubMed ID: 15011897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Myelodysplastic syndromes--new treatment options].
    Germing U
    Med Klin (Munich); 2006 Mar; 101 Suppl 1():123-6. PubMed ID: 16802536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical implications of the World Health Organization's classification of myelodysplastic syndromes.
    Komrokji RS; Bennett JM
    Curr Hematol Rep; 2005 May; 4(3):175-81. PubMed ID: 15865868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of patients with higher risk myelodysplastic syndromes.
    Fukumoto JS; Greenberg PL
    Crit Rev Oncol Hematol; 2005 Nov; 56(2):179-92. PubMed ID: 15979321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating myelodysplastic syndromes.
    Ryan C; McCann S
    IDrugs; 2005 Apr; 8(4):320-6. PubMed ID: 15800807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternatives to conventional or myeloablative chemotherapy in myelodysplastic syndrome.
    Cazzola M
    Int J Hematol; 2000 Aug; 72(2):134-8. PubMed ID: 11039660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.
    Silverman LR; McKenzie DR; Peterson BL; Holland JF; Backstrom JT; Beach CL; Larson RA;
    J Clin Oncol; 2006 Aug; 24(24):3895-903. PubMed ID: 16921040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review.
    Oliansky DM; Antin JH; Bennett JM; Deeg HJ; Engelhardt C; Heptinstall KV; de Lima M; Gore SD; Potts RG; Silverman LR; Jones RB; McCarthy PL; Hahn T
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):137-72. PubMed ID: 19167676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in myelodysplastic syndromes.
    Shadduck RK; Latsko JM; Rossetti JM; Haq B; Abdulhaq H
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):137-43. PubMed ID: 17379099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.